Monitor mid-2026 topline data from ongoing trials as the next major catalyst; current financials reflect investment phase with no near-term profitability, but cash runway supports development without immediate dilution risk.
Price Chart
Executive Summary
Sionna Therapeutics reported financial results for Q4 and full year 2025, highlighting increased R&D and G&A spending, a growing net loss, and a strong cash position of $310.3 million that funds operations into 2028. The company advanced its NBD1 stabilizer pipeline with Phase 1/2a trials on track for mid-2026 readouts, but no revenue-generating products or positive clinical outcomes were reported.
Key Financial Metrics
Key Facts
- No revenue generated; biopharma company in clinical stage with no commercial products
- Net loss increased to $75.3 million in 2025 from $61.7 million in 2024
- Cash and equivalents totaled $310.3 million as of December 31, 2025, up from $168.0 million in 2024
- SION-719 and SION-451 Phase 1 trials completed with topline data expected mid-2026
- R&D expenses rose to $60.3 million in 2025 from $57.3 million in 2024
- G&A expenses nearly doubled to $28.7 million in 2025 from $13.3 million in 2024
Financial Impact
Increased operating losses and higher G&A due to growth initiatives; cash runway extended to 2028
Risk Factors
- Clinical trial failure risk for SION-719 and SION-451 in mid-2026 readouts
- Increasing net losses and lack of revenue may pressure valuation if trials underperform
- Heavy reliance on successful development of unproven NBD1 stabilizer mechanism
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247220 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $4.50 $7.30 | ▼ −62.22% | ▼ −63.14% | $5.04 (−12.00%) |
Aug 6, 2026 8w ago | 8-K | $49.61 $6.75 | ▼ −86.39% | ▼ −86.99% | $5.04 (−89.84%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▲ +12.70% | ▲ +10.27% | $5.04 (−88.87%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▼ −12.70% | ▼ −10.27% | $5.04 (+88.87%) |
Jul 7, 2026 12w ago | Insider Cluster | $44.00 $47.34 | ▼ −7.59% | ▼ −4.32% | $5.04 (+88.55%) |
Jul 2, 2026 13w ago | Insider Cluster | $43.99 $46.78 | ▲ +6.34% | ▲ +6.76% | $5.04 (−88.54%) |
Jun 11, 2026 16w ago | Institutional Cluster | $36.05 $44.94 | ▲ +24.66% | ▲ +22.77% | $5.04 (−86.02%) |
May 30, 2026 17w ago | Insider Cluster | $40.90 $43.99 | ▲ +7.55% | ▲ +8.85% | $5.04 (−87.68%) |
May 29, 2026 17w ago | 144 | $40.90 $43.99 | ▼ −7.55% | ▼ −8.85% | $5.04 (+87.68%) |
May 12, 2026 20w ago | 8-K | $40.94 $34.03 | ▼ −16.88% | ▼ −15.15% | $5.04 (−87.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access